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We present an approach for genome-wide association analysis with improved power on theWellcome Trust
data consisting of seven common phenotypes and shared controls. We achieved improved power by
expanding the control set to include other disease cohorts, multiple races, and closely related individuals.
Within this setting, we conducted exhaustive univariate and epistatic interaction association analyses. Use
of the expanded control set identified more known associations with Crohn’s disease and potential new
biology, including several plausible epistatic interactions in several diseases. Our work suggests that
carefully combining data from large repositories could reveal many new biological insights through
increased power. As a community resource, all results have been made available through an interactive web
server.
M
ost genome-wide association studies consider associations between single-nucleotide polymorphisms
(SNPs) and phenotype, one SNP at a time. Increasingly, however, studies are going beyond such low-
hanging fruit to richer hypotheses, so as to better understand the causes of complex disease traits. For
example, considering pairwise epistatic effects has yielded promising results1–4. One challenge with exhaustive
pairwise analyses is the tremendous amount of statistical power needed to identify associations that can survive
the multiple-testing correction. In the Wellcome Trust Case Control Consortium (WTCCC) data5, for example,
there are over 60 billion pairs of SNPs that can be tested for association, requiring a P value of less than 83 10213
for significance under Bonferroni correction. One way to address the multiple-testing issue is by way of a two-
stage approach, wherein SNP pair hypotheses are pre-filtered with prior knowledge in the first stage, and only the
remaining pairs are tested in the second stage6. Although such filtering approaches incur a reduced burden from
multiple testing, they are susceptible tomissing true causal tests by virtue of their inherently imperfect filtering. In
this article, we describe an alternative approach that, rather than reducing the number of tests, increases statistical
power by making more efficient use of the available data. We developed this approach while looking for epistatic
effects in the WTCCC data and present our results on this data, making them fully available as an on-line public
resource.
Our strategy for increasing power, while relatively simple in concept, required state-of-the-art analysis tech-
niques and computational resources to implement. Previous epistatic analyses of WTCCC excluded a large
number of useable data. Specifically, the other studies discarded (1) individuals from disease cohorts other than
the one being studied and (2) non-Caucasian individuals and closely related individuals. We now explain why
previous studies did not use these individuals and how our approach enabled us to include them.
To understand the first exclusion of individuals in the standard analysis, note that theWTCCC data consists of
genome-wide SNPs and phenotypes for seven common diseases: bipolar disorder (BD), coronary artery disease
(CAD), hypertension (HT), Crohn’s disease (CD), rheumatoid arthritis (RA), type-I diabetes (T1D), and type-II
diabetes (T2D). TheWTCCC took great care to consistently use the same data pipeline so as to enable sharing of a
common control set for all phenotypes, one of the main contributions of the initial study5. The standard analysis
of these data considers each disease phenotype separately. That is, when analyzing a given disease, individuals
with that disease (the cases) are always compared with a single, fixed, set of control individuals. In contrast, for a
given phenotype, we increase the size of the control set by including all other phenotype cohorts.When expanding
the controls in this way, pleiotropy could lead to decreased power. In particular, if a SNP were associated with the
disease corresponding to the cases and also with one of the diseases in the expanded controls (with an effect in the
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same direction), then the resulting association strength would be
attenuated. We call this effect negative crosstalk. Expanding the con-
trols could also lead to spurious associations. Specifically, when ana-
lyzing a particular phenotype, one could find association signal
arising from any of the other diseases only because these are now
embedded in the expanded control set, an effect we call positive
crosstalk. Although both negative and positive cross-talk are undesir-
able, there are straightforward procedures for detecting and elim-
inating them. For example, to mitigate the effects of positive
crosstalk, one can look at hypotheses that appear to be pleiotropic
in the standard series of analyses, and remove all but the most sig-
nificant from consideration in the expanded analysis. Tomitigate the
effects of negative crosstalk and inappropriate removal due to pos-
itive crosstalk, one could additionally run the analysis on the non-
expanded control set.
The second exclusion of non-Caucasian and closely-related indi-
viduals is done to avoid confounding by population structure and
family relatedness, respectively. The exclusion of these individuals
enables the use of simple, fast statistical methods such as linear or
logistic regression for the identification of associations. To properly
analyze data containing population structure and family relatedness,
one could use a linear mixed model (LMM)7,8—a model so compu-
tationally expensive that, up until our recent work, it could not be
deployed on large data sets9–11. Now that our LMMs have the same
computational complexity as linear regression, however, we are able
to include the formerly excluded individuals and increase power.
Results
We first investigated the improved power offered by our approach on
the analysis of univariate associations in the WTCCC data for
Crohn’s disease because there is a bronze standard (a large meta-
analysis) with which to evaluate such results12. We assessed our
approach by counting false positives and true positives on a locus-
by-locus basis. A standard analysis (i.e., with both exclusions in place
and using linear regression) yielded 0 false positive loci and 6 true
positive loci. Expanding the control set to include individuals in the
remaining six diseases (but still excluding non-Caucasians and clo-
sely related individuals) yielded 2 false positive and 13 true positive
loci. These false positives did not correspond to significant loci in any
of the other six diseases (see Supplementary Dataset 1), suggesting
that positive crosstalk was not responsible. We therefore posited that
the false positives were due to confounders in the expanded control
set without the use of a method to correct for them. To test this
hypothesis, we applied a LMM on this same data set to correct for
them. In doing so, we obtained 1 false positive locus (one less than
without the LMM) and (again) 13 true positive loci, suggesting that
the LMM did in fact correct for confounding. Finally, removing the
second exclusion (i.e., additionally including non-Caucasians and
close family members) resulted in 0 false positives and 13 true
positives.
In summary, we went from a standard analysis with 6 true posi-
tives (and 0 false positives) to our expanded analysis with 13 true
positives (and 0 false positives). Significant univariate associations
for Crohn’s disease and the remaining six phenotypes are given in
Supplementary Dataset 2. Although we found evidence of positive
crosstalk within these univariate analyses (see Supplementary
Dataset 2), as we shall see, we did not see such evidence for epistatic
interactions.
Given the improvement we saw on univariate associations for
Crohn’s disease, we next applied our expanded approach to the
analysis of epistatic interactions for all seven phenotypes (Supple-
mentary Dataset 3). We observed significant (P , 7.9 3 10213)
epistatic interactions for all but the CD phenotype, with no substan-
tial inflation or deflation of P values (Supplementary Figure 1). As
noted by Wan et al.1, apparent epistatic interactions for SNP pairs
that are too close (within 1 Mb) to each other are potentially false
positives due to linkage. Consequently, we removed such associa-
tions from further consideration, leaving only those that were well
Figure 1 | T1D epistatic interactions in the MHC region. Each point corresponds to a significant, well separated, epistatic interaction
in the extendedMHC region. Positions of the two SNPs are shown on the x and y axes. Regions on the x-axis corresponding toMHC class I and class III are
shaded. All positions shown on the y-axis fall in MHC class II region.
www.nature.com/scientificreports
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separated. After this proximity filter, epistatic interactions remained
for each of the six phenotypes (see Table 1). Furthermore, none of
these associations were found to have possible positive crosstalk, thus
mitigating concerns about this issue. Note that almost all RA epistatic
interactions were in the MHC class II region, but that none of these
were well separated. In contrast, many T1D epistatic interactions
were well separated, and showed interactions between MHC class I
(29.8 Mb–31.6 Mb) and class II (32.3 Mb–33.4 Mb) as well as inter-
actions between MHC class III (31.6 Mb–32.3 Mb) and class II
(Figure 1), which may have clinical significance as discussed in
Wan et al.1.
A standard approach for avoiding the onerous computations
needed for an exhaustive epistatic analysis is to first exclude SNPs
having single-SNP associations with a P value greater than some
threshold, and then testing only SNP pairs for those SNPs not
excluded13. Our exhaustive analysis provides an opportunity to
evaluate such an approach. In particular, had we used this approach
with the rather liberal P value threshold of 1026, we would have
missed all of the significant epistatic interactions for five of the phe-
notypes (BD, CAD, HT, RA, and TD2) (Table 1).
Overall, the results discussed so far are generally consistent with
those ofWan et al.1 who performed an exhaustive search for epistatic
interactions on the standard WTCCC data. One difference in results
between their analysis and ours is that we did not find the one epi-
static interaction in the CD phenotype previously found, which has
so far not had any biological support. Another difference is that our
analysis found one epistatic interaction in the bipolar disorder
phenotype not previously found—in particular, between SNP
rs7496665 (on chromosome 15) and SNP rs6142704 (on chro-
mosome 20), the latter of which is in gene CDH4 and thought to
play an important role in brain segmentation and neuronal out-
growth.
The most conspicuous difference between our results and those of
Wan et al.1 was that we found 42 epistatic interactions for the CAD
phenotype (Supplementary Dataset 2), whereas they found none.
Among these epistatic interactions, 12 had both SNPs within the
same gene, significantly more than one would find due to chance
(P 5 0.018). Two SNPs are of particular interest because they
appeared in many epistatic interactions. The first, rs3798343,
appeared in six of the epistatic interactions, and is within gene
PPARD, previously linked to CAD14. The second, rs17146094,
appeared in 15 of the interactions, and is within 100 Kb of gene
LIMK1, which has also been previously linked to CAD15.
Furthermore, these two apparent ‘‘hub’’ SNPs interact strongly with
each other (P5 9.43 10218). Finally, we note thatWan et al.1, used a
different statistical test for epistasis (see Methods) which may
account for some of the differences, although most differences came
from our use of the expanded data (Supplementary Dataset 4).
Finally, the genomic-control factor l16,17 indicated apparent infla-
tion for the univariate tests, with l ranging from 1.06 to 1.18 across
the seven phenotypes. In contrast, the tests for epistatic interactions
showed no inflation, with values of l all less than 1.01 (Supple-
mentary Figure 1). There is a growing consensus that apparent uni-
variate inflation is actually the result of a large number of small
polygenic effects on the phenotype18, rather than due to uncontrolled
confounders. The near 1.0 values of l suggest that epistatic effects are
not as frequent as univariate ones.
Although we have provided the list of all epistatic interactions
found to be significant (Supplementary Dataset 3), researchers
interested in particular SNP-SNP or gene-gene interactions may
wish to access association P values below our threshold. We provide
such access (and access to all univariate associations) by way of an
online tool at http://research.microsoft.com/en-us/um/redmond/
projects/MSCompBio/.
Discussion
Using data from the Wellcome Trust, we have demonstrated that
statistical power can be substantially improved by expanding the
control set. This type of expansion should be possible for datasets
in large repositories including dbGap. For example, one could com-
bine SNP data obtained from the same platform, although further
care would have be taken than in theWTCCC context to ensure that
batch effects from sample collection, preparation, and analysis were
adequately addressed. Procedures similar to the ones described here
are likely to help in this regard, although this approach remains an
open area of investigation.
Methods
We used data from the Wellcome Trust Case Control Consortium (WTCCC) with
their permission. The data consisted of the SNP and phenotype data for seven
common diseases: bipolar disorder (BP), coronary artery disease (CAD), Crohn’s
disease (CD), hypertension (HT), rheumatoid arthritis (RA), type-I diabetes (T1D),
and type-II diabetes (T2D). Each phenotype group contained about 1,900 individuals.
In addition, the data included a set of approximately 1,500 controls from the UK
Blood Service Control Group (NBS). The data did not include a second control group
from the 1958 British Birth Cohort (58C), as permissions for it precluded use by
commercial organizations.
Note that additional quality control is warranted when testing for epistatic inter-
actions due sparse counts in contingency tables19. Although our expansion of the data
somewhat mitigates this need, we did impose stricter quality control. In particular, in
addition to the filters described by the WTCCC5, we excluded a SNP if either its
minor-allele frequency was less than 1%, or it was missing in greater than 1% of
individuals (in both cases on the fully expanded data). Also, because genetic distances
were required by FaST-LMM to avoid proximal contamination9,10, we excluded SNPs
whose genetic distance were unknown. After filtering, 356,441 SNPs remained. In
total, there were 14,925 individuals across the seven phenotypes and the control set.
All analyses assumed an additive effect of a SNP on the phenotype, using a 0/1/2
encoding for each SNP (indicating the number ofminor alleles for an individual). The
data for each SNP was preprocessed by subtracting the mean and dividing by the
standard deviation. A missing SNP observation was set to a value of zero after pre-
processing. A likelihood ratio test was used to compute P values. In our test for
epistasis, the null model consisted of an additive model with a fixed effect for each
SNP, while the alternative model additionally included a fixed effect corresponding to
the product of the preprocessed values of each of the two SNPs. In univariate analyses,
we used the genome-wide significance threshold from the original analysis (P, 53
1027)5. In the epistatic interaction analyses, we used a Bonferroni-corrected threshold
(P , 7.9 3 10213) for the 63,525,271,461 tested pairs. For comparison, we imple-
mented the epistasis test ofWan et al.1, which also used an LRT, but with different null
and alternative models than ours. Their null model was equivalent to a logistic
regression on the phenotype using a one-hot encoding of the three states of each SNP
(five parameters). Their alternative model was the saturated model—that is, one
parameter for each of the 3 3 3 combinations of {0,1,2} 3 {0,1,2}. Therefore, their
final test had four degrees of freedom.
In our analyses, we used a linear mixed model (LMM) with a Gaussian likelihood.
Technically, this model is not well suited to the analysis of case-control phenotypes as
found in the Wellcome Trust data. Nonetheless, both theoretical and empirical work
have demonstrated that use of the Gaussian form performs well on such data8,20. The
LMM log likelihood of the phenotype data, y (dimension n3 1), given fixed effects X
Table 1 | Number of Epistatic interactions. Number of epistatic
interactions across the seven WTCCC phenotypes for different
levels of filtering of the SNP pairs. The column "All" contains the
number of associations that were significant after Bonferroni cor-
rection. The column "Well separated" contains the number of asso-
ciations after further filtering out the interactions that were not well
separated (seeMethods). The column "Weakmarginal(s)" contains
the number of associations after further excluding SNP pairs that
would have been identified by a two-stage marginal-filtering
approach
Phenotype All Well separated Weak marginal(s)
BD 6 1 1
CD 0 0 0
CAD 56 42 42
HT 5 1 1
RA 71 4 4
T1D 2181 656 15
T2D 4 3 3
Total 2323 707 66
www.nature.com/scientificreports
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(dimension n 3 d), which include the SNP, the covariates, and the column of ones
corresponding to the bias (offset), can be written as
LL s2e ,s
2
g ,b
 
~ logN yjXb; s2gKzs2e I
 
ð1Þ
where N (rjm; S) denotes a Normal distribution in r with mean m and covariance
matrixS;K (dimension n3 n) is the genetic similaritymatrix; I is the identity matrix;
s2e (scalar) is themagnitude of the residual variance; s
2
g (scalar) is themagnitude of the
genetic variance; and b (dimension d 3 1) are the fixed-effect weights.
We used FaST-LMM-Select9,10 for the LMM analyses (code and executables
available at http://mscompbio.codeplex.com). The algorithm selected 0, 1, 310, 440,
75, 400, and 29 SNPs for the genetic similarity matrix, for the BD, CAD, CD, HT, RA,
T1D, and T2D phenotypes, respectively. For the univariate analysis, we used a 2
centimorgan exclusion window to avoid proximal contamination.
We performed the epistatic analyses using 28,000 cores onWindowsAzure (http://
www.windowsazure.com/en-us/) with theHPC Server Azure burst solution. The runs
across all seven phenotypes required 950 compute years, with a wall-clock time of 13
days. Each of the seven runs produced over two terabytes of data.
The calibration of P values was assessed using quantile-quantile plots and the
genomic control factor l. The value l is defined as the ratio of the median observed
test statistic to the median theoretical test statistic under the null distribution. When
there is no signal in the data, a calibrated result corresponds to l5 1.0, and values of l
substantially greater than (less than) 1.0 are indicative of inflation (deflation).
We used chromosome positions to map SNPs to genes. Specifically, we used the
latest GRCh37 assembly from UCSC Genome Browser (http://genome.ucsc.edu/) for
genes, and dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) for SNPs. When a
gene had multiple definitions in the UCSC Genome Browser, we chose the one
referenced by the HUGO Gene Nomenclature Committee at the European
Bioinformatics Institute (http://www.genenames.org).
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CORRIGENDUM: An Exhaustive Epistatic SNP Association Analysis on
Expanded Wellcome Trust Data
Christoph Lippert, Jennifer Listgarten, Robert I. Davidson, Jeff Baxter, Hoifung Poon, Carl M. Kadie & David Heckerman
The authors have noticed that the original version of this Article contained a typographical error in the spelling of
the author Hoifung Poon which was incorrectly given as Hoifung Poong. Furthermore, the author Jeff Baxter was
incorrectly listed as Scott Baxter. These changes have now been corrected in both the PDF and HTML versions of
the Article.
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